# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and grante...
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled ...
HC Wainwright & Co. analyst Oren Livnat reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $200 pric...
Barclays analyst Balaji Prasad maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target fr...
Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $222 price target.